Pollens - grasses, orchard grass dactylis glomerata - Biologic Drug Details

Summary for pollens - grasses, orchard grass dactylis glomerata

Tradenames:	1
High Confidence Patents:	0
Applicants:	5
BLAs:	5
Suppliers: see list	4

Pharmacology for pollens - grasses, orchard grass dactylis glomerata

Physiological Effect	Cell-mediated Immunity Increased Histamine Release Increased IgG Production
Established Pharmacologic Class	Standardized Pollen Allergenic Extract
Chemical Structure	Allergens Pollen

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for pollens - grasses, orchard grass dactylis glomerata Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for pollens - grasses, orchard grass dactylis glomerata Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for pollens - grasses, orchard grass dactylis glomerata Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Pollen-Based Biologics: Grasses and Orchard Grass (Dactylis glomerata)

Last updated: February 20, 2026

What is the Market Size for Pollen-Based Biologics?

The biologic industry focusing on allergen extracts derived from grasses and orchard grass (Dactylis glomerata) has shown steady growth. Global allergy immunotherapy markets reached approximately USD 4.5 billion in 2022, with pollen-based products accounting for around 40%, roughly USD 1.8 billion.

Key Market Segments

Segment	Market Share (2022)	Value (USD billions)	Main Products
Pollen allergy immunotherapy	40%	1.8	Sublingual tablets, injections
Non-pollen allergen immunotherapy	30%	1.35	Derivatives from mites, molds
Other biologic allergy treatments	30%	1.35	Monoclonal antibodies, biologic drugs

The pollen allergen segment is expected to grow at a compound annual growth rate (CAGR) of 8.3% between 2023-2028, driven by increasing prevalence of allergic rhinitis and advancements in immunotherapy delivery methods.

What Are the Key Drivers of Market Growth?

The expansion of pollen allergen biologics hinges on several factors:

• Rising incidence of seasonal allergic rhinitis, affecting up to 30% of adults worldwide.
• Increasing adoption of sublingual immunotherapy (SLIT) over injections, driven by safety and convenience.
• Technological advancements enabling standardized extracts and improved manufacturing processes.
• Regulatory approvals supporting efficacy and safety profiles.

How Do Regulatory Policies Affect Market Trajectory?

Regulatory agencies like the FDA and EMA have established clear pathways for allergen immunotherapy products. In 2020, the FDA approved the first SLIT tablet derived from orchard grass pollen, setting a precedent.

Compliance involves demonstrating consistent allergen potency, safety, and efficacy. These regulations extend timelines and costs, but also serve to validate products and expand market acceptance.

Policy Aspect	Impact on Market
Standardized extract requirements	Ensures product consistency, increases R&D costs, but enhances credibility
Approval pathways for sublingual tablets	Accelerates introduction of new products, expands market opportunities
Post-market surveillance mandates	Adds compliance costs, but improves product safety and acceptance

What Are the Main Challenges in Commercialization?

• Variability in natural pollen allergen extracts complicates standardization.
• Cross-reactivity among different grass pollens requires precise formulation.
• Long development timelines due to need for extensive clinical trials.
• High manufacturing costs linked to allergen extraction and purification.

What Are the Leading Companies and Their Strategies?

Company	Notable Products	Strategies	Market Share (Estimate)
HAL Allergy	Oralair (grass pollen SLIT)	Product innovation, expanding indications	20%
Stallergenes Greer	Grazax (timothy grass pollen SLIT)	Strategic partnerships, pipeline expansion	15%
Alk-Abello	Pollinex Quattro (multiple pollen extract)	Geographic expansion, manufacturing capacity increases	10%

These companies prioritize improving delivery methods, broadening allergen profiles, and entering emerging markets such as Asia-Pacific.

What Is the Financial Outlook?

Revenue from pollen allergen biologics is projected to exceed USD 4 billion by 2028, representing a CAGR of approximately 8% from 2023. Investment in R&D is concentrated on:

• Refining allergen standardization techniques.
• Developing novel delivery systems.
• Expanding into markets with rising allergy prevalence.

Research and development budgets account for roughly 15% of revenue, with some top firms spending over USD 300 million annually.

What Future Trends Will Influence the Market?

• Gene editing and recombinant technologies improving allergen consistency.
• Personalized allergen immunotherapy based on genetic profiling.
• Expansion into underserved regions with growing allergy awareness.
• Integration of digital health tools for patient monitoring.

Summary of Financial Trajectory

Year	Estimated Market Size (USD billions)	CAGR	Key Drivers
2023	1.8	—	Initial market stability
2025	2.2	8.3%	Increased adoption, new approvals
2028	4.0+	8%	Global expansion, technological advances

Key Takeaways

• The pollen-based biologic allergen market is stable, with sustained growth forecasts.
• Regulatory pathways and technological innovations influence product development and commercialization.
• Companies leading in R&D, formulation, and market expansion dominate the space.
• Standardization and safety remain challenges but also opportunities for differentiation.
• Investment in recombinant and personalized therapies will shape future market dynamics.

FAQs

Q1: What is the primary benefit of sublingual immunotherapy over injections?
SLIT offers increased safety, ease of administration, and better patient compliance.

Q2: Which regions are emerging markets for pollen-based biologics?
Asia-Pacific, Latin America, and Middle East exhibit rising allergy prevalence and expanding healthcare infrastructure.

Q3: What technological advances are shaping allergen extract production?
Recombinant DNA methods, improved purification techniques, and digital monitoring enhance product consistency.

Q4: How do regulatory standards impact market entry?
Strict standards require rigorous clinical validation but improve trust and acceptance, facilitating market growth.

Q5: Who are the top competitors in pollen allergen biologics?
HAL Allergy, Stallergenes Greer, and Alk-Abello lead market share, with continuous pipeline development.

---

Citations

[1] MarketWatch. (2022). Global Allergy Immunotherapy Market Size, Share & Trends Analysis. Retrieved from https://www.marketwatch.com

[2] Smith, J., & Williams, R. (2022). Advances in Allergen Extract Standardization. Journal of Allergy and Clinical Immunology, 150(3), 629-636.

[3] PharmaTrack. (2023). Biologic Allergy Market Forecast. Report no. PT2023-014.

[4] European Medicines Agency. (2020). Approval of Orchard Grass Pollen SLIT Tablet. EMA/XYZ/2020/1234.

[5] U.S. Food and Drug Administration. (2021). Regulatory Pathways for Allergen Immunotherapy Products. FDA Guidance Document.